All Articles

On behalf of the Editorial Board of the Journal of Oncology Navigation & Survivorship (JONS), it's my pleasure to offer the current issue. Each month, we aim to present navigators with an array of topics relevant to their practice. To achieve our goal, we publish original navigation research, treatment updates, interviews, and navigation best practices. Some highlights from the current issue follow.
Read More



The authors present the results from their study of caregivers’ involvement in treatment decision-making and their need for help in making care decisions as well as communicating with the patient and healthcare team.
Read More

Do administrators really understand the needs of the navigator, and are they fully aware of the infrastructure needed for their navigation programs? In a discussion on administrative engagement in navigation programs at the AONN+ Midyear Conference, Tricia Strusowski, RN, MS, posed these and other provocative questions to attendees.
Read More

New prostate cancer guidelines issued by the National Comprehensive Cancer Network (NCCN) continue to support early detection efforts in well-informed, healthy men while acknowledging that optimal screening of high-risk patients is not completely known. The guidelines also support the use of active surveillance in men who have low-risk prostate cancer.
Read More

HIV status alone should not be used for cancer treatment decision-making, according to the first guidelines from the National Comprehensive Cancer Network (NCCN) on the management of cancer in persons infected with HIV
Read More

The delivery and receipt of cancer care in value-based healthcare models was the subject of a roundtable discussion at the National Comprehensive Cancer Network (NCCN) 23rd Annual Conference.
Read More

Ensuring Consistent and Reliable Biomarker Testing
In the main article of this publication, the current state of programmed-cell death-1 and programmed-cell death ligand-1 (PD-L1) testing, evasion by tumors of the immune system, and the study and use of immune checkpoint inhibitors across multiple tumor types are expertly summarized.
Read More

The Evolving Role of PD-L1 Testing in Patients with Cancer
Clearly, immunotherapy has come of age in multiple tumor types, as described in the main article in this publication. The question now is how to develop more personalized immunotherapy and use biomarkers to identify patients most likely to benefit from this therapy.
Read More

Page 198 of 283

Journal of Oncology Navigation & Survivorship
JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country